The glucocorticoid receptor, encoded by the NR3C1 gene, sits at the intersection of the hypothalamic-pituitary-adrenal (HPA) axis, the body’s central stress circuitry, and the immune system. When the brain perceives stress, the axis releases cortisol, which binds GR in cells throughout the body and brain, altering which genes are transcribed. Textbook immunology has long cast this system as anti-inflammatory, and corticosteroid drugs remain among the most widely prescribed immunosuppressants in medicine. But the authors assemble evidence that this framing is incomplete. Acute GR activation does dampen inflammatory responses and restore homeostasis, yet chronic or dysregulated activation can do the opposite: it sensitizes innate immune pathways, lowers the threshold at which immune cells respond to future challenges, and amplifies inflammation rather than resolving it.

Central to this reframing is the concept of inflammatory priming. In the primed state, prior exposures—psychological stress, infection, metabolic overload, or substance withdrawal—do not merely trigger a transient inflammatory burst; they reconfigure the immune system so that subsequent challenges produce exaggerated and prolonged responses. One proposed mechanism involves glucocorticoids acting as what researchers have called alarm signals of danger, preparing innate immune pathways for anticipated threats. Stress also releases danger-associated molecular patterns such as HMGB1, intracellular molecules that, when released into circulation, further tune the immune system toward heightened reactivity. The result is a self-reinforcing loop in which the stress axis and the inflammatory machinery keep each other engaged long after the original insult has passed.

At the molecular level, the transcription factor NF-κB emerges as the critical integrator. NF-κB controls the expression of cytokines including interleukin-1, interleukin-6, and tumor necrosis factor, and its chronic activation is a hallmark of sustained inflammation. Experimental work cited in the perspective shows that chronic unpredictable stress exacerbates lipopolysaccharide-induced NF-κB activation in the frontal cortex and hippocampus, via glucocorticoid secretion—demonstrating mechanistically how stress-axis dysregulation feeds directly into inflammatory amplification within the brain. Microglia, the resident immune cells of the central nervous system, appear to be particularly consequential at this interface: after glucocorticoid exposure they become sensitized, mounting exaggerated inflammatory responses to later stimuli, a shift that has been implicated in dopaminergic neurodegeneration in models of parkinsonism.

The therapeutic corollary of this framework is subtle and, the authors stress, counterintuitive. If dysregulated GR signaling drives inflammatory priming, then the goal is not maximal blockade of the receptor, as conventional antagonism would achieve, but partial, selective modulation that restores regulatory balance while preserving the receptor’s essential physiological functions. The perspective highlights PT150, a small-molecule GR modulator formerly known as Org 34517, originally developed for neuropsychiatric indications. Unlike a complete antagonist, PT150 alters receptor-dependent transcriptional signaling without fully suppressing glucocorticoid activity. Because GR functionally interacts with NF-κB-associated transcriptional networks, modulating the receptor offers a plausible route to influence downstream inflammatory signaling—though the authors caution that the precise molecular mechanisms linking the compound’s GR interaction to the observed inflammatory effects remain incompletely defined.

What gives the hypothesis its force is convergence. Across independently developed experimental platforms—unbiased transcriptomic analyses, REACTOME and MSigDB pathway enrichment studies, protein-signaling assays, primary glial cell systems, animal models, and early human pharmacology—selective GR modulation with PT150 and a related dimer, PT157, consistently produced the same signature: attenuation of NF-κB-associated inflammatory pathways, including TAK1/IKK signaling, p38 MAPK stress responses, and IL-1, IL-6, TNF, and chemokine signaling, alongside preservation of interferon-related host-defense pathways and enhancement of selected repair programs. In animal work, the compound reduced innate immune inflammatory responses in the Syrian hamster model of SARS-CoV-2 infection and altered fentanyl self-administration and stress-induced drug seeking in rodents exposed to early-life stress. The consistency of this pattern across biologically dissimilar systems, the authors argue, supports dysregulated GR signaling as a tractable upstream regulator rather than a disease-specific curiosity.

The authors are notably candid about the limits of their evidence. Support for GR dependence derives from sponsor-associated, non-peer-reviewed studies in primary glial cells, in which suppression of NF-κB activation following PT150 exposure was substantially diminished after knockdown of NR3C1—interpreted as evidence of target dependence, but flagged as preliminary pending independent replication. The compound has also been characterized as a modulator of the androgen receptor, a related steroid receptor with overlapping transcriptional networks, leaving unresolved how much of the observed effect reflects GR activity alone versus combined GR and androgen receptor modulation. COX-2, a classical downstream inflammatory enzyme, is treated in the framework as a potential marker within the broader network rather than a direct target. These caveats matter: the perspective explicitly frames itself as presenting a testable biological hypothesis, not established therapeutic efficacy across the many conditions it discusses.

Human data, while early, add an intriguing dimension. In a Phase II study of Org 34517 in major depressive disorder, two flexible-dose regimens produced divergent results: the higher-dose regimen drove substantially greater elevations in circulating cortisol, consistent with stronger compensatory HPA-axis activation following more extensive receptor blockade, while the lower-dose regimen kept cortisol lower and showed more favorable outcomes on selected clinical measures in exploratory analyses. The authors read this as suggestive of a therapeutic window—too little modulation may leave priming intact, too much may provoke counterproductive endocrine compensation. Across clinical development programs involving roughly 970 participants, no drug-related serious adverse events have been reported, and an FDA investigational new drug application was obtained for evaluation in viral pneumonia. The subgroup analyses, however, were exploratory and not powered to establish differential efficacy, so the window hypothesis remains prospective rather than proven.

The framework’s most consequential prediction is that treatment responsiveness will depend more on biological state than on diagnostic category. If inflammatory priming is the shared mechanism, then the patients most likely to benefit from selective GR modulation are those whose stress axes are measurably dysregulated—regardless of whether their presenting diagnosis is depression, long COVID-style post-infectious inflammation, addiction, obesity, or a malignancy. The authors propose a biomarker-guided path forward: cortisol awakening responses, dexamethasone suppression testing, ACTH concentrations, cerebrospinal fluid corticotropin-releasing factor, cytokine profiles, and NF-κB-associated transcriptional signatures could all serve to stratify patients and quantify target engagement in prospective, dose-ranging trials. Such designs would directly test whether partial modulation of a dysregulated receptor can restore inflammatory and neuroendocrine homeostasis more effectively than maximal antagonism—an approach aligned with precision medicine’s broader shift toward classifying patients by underlying biology rather than conventional diagnostic labels.

Whether the hypothesis survives prospective testing will determine whether GR modulation becomes a broadly applicable host-directed therapeutic paradigm or remains a context-dependent intervention for a narrower set of indications. The evidence base is uneven: post-infectious syndromes, addiction, and stress-associated neuropsychiatric conditions rest on relatively strong mechanistic and translational ground, while applications in oncology, metabolic disease, ALS, and autism spectrum disorder remain substantially less mature, supported largely by transcriptomic and computational analyses. But the core proposition—that a single receptor sitting between the stress system and the immune system helps set the inflammatory tone of chronic disease—is now stated clearly enough to be falsified. If biomarker-defined trials confirm that recalibrating the glucocorticoid receptor can reproducibly shift patients out of the primed inflammatory state, medicine may gain something it has lacked: a way to treat the shared soil of chronic disease rather than pulling its many weeds one at a time.

Subject of Research: Glucocorticoid receptor modulation as a host-directed therapeutic strategy for inflammatory priming across chronic diseases

Article Title: Glucocorticoid receptor modulation as a host-directed strategy for inflammatory priming across chronic disease states

Article References: Slayden, R. A., Tjalkens, R. B., Theise, N. D., Verrico, C. D., Azevedo, E. P., Van Drie, J. H., Bardo, M. T., Prendergast, M. A., Butt, C. M., Altschul, R., Nair, S. S., Chakravarty, D., & Tewari, A. K. (2026). Glucocorticoid receptor modulation as a host-directed strategy for inflammatory priming across chronic disease states. Frontiers in Pharmacology, 17, Article 1931270. https://doi.org/10.3389/fphar.2026.1931270

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1931270

Keywords: glucocorticoid receptor, chronic inflammation, HPA axis, NF-κB, neuroinflammation, inflammatory priming, PT150, host-directed therapy, cortisol, microglia, NR3C1, precision medicine